SC
CRVS icon

Steven Cohen’s Corvus Pharmaceuticals CRVS Stock Holding History

Steven Cohen’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,875,000
Closed -$22.1M – 3890
2025
Q4 		$22.1M Sell
2,875,000
-3,579,274
-55% -$28.2M 0.02% 816
2025
Q3 		$47.6M Sell
6,454,274
-588,099
-8% -$3.01M 0.08% 279
2025
Q2 		$28.2M Buy
7,042,373
+4,254,742
+153% +$15.5M 0.06% 386
2025
Q1 		$8.86M Sell
2,787,631
-242,380
-8% -$1.14M 0.02% 728
2024
Q4 		$16.2M Sell
3,030,011
-2,532,718
-46% -$18.9M 0.04% 531
2024
Q3 		$29.4M Sell
5,562,729
-401,781
-7% -$1.44M 0.07% 310
2024
Q2 		$10.9M Buy
+5,964,510
New +$11.1M 0.03% 578
2022
Q2 		– Sell
-745,000
Closed -$1.22M – 1434
2022
Q1 		$1.22M Sell
745,000
-50,000
-6% -$91.5K ﹤0.01% 935
2021
Q4 		$1.92M Buy
795,000
+220,000
+38% +$853K 0.01% 827
2021
Q3 		$2.78M Buy
+575,000
New +$1.7M 0.01% 753
2017
Q4 		– Sell
-195,034
Closed -$3.11M – 924
2017
Q3 		$3.11M Sell
195,034
-37,349
-16% -$517K 0.01% 617
2017
Q2 		$2.81M Sell
232,383
-175,894
-43% -$1.88M 0.02% 596
2017
Q1 		$8.48M Buy
+408,277
New +$6.4M 0.05% 431

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Steven Cohen's CRVS Position: Q1 2026 in Review

Steven Cohen sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 2,875,000 shares — an estimated $22.1M sold.

Steven Cohen first reported a position in CRVS in Q1 2017 and held it in 13 quarters. The position peaked at $47.6M in Q3 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Steven Cohen reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 2,875,000 Corvus Pharmaceuticals shares in Q1 2026, an estimated $22.1M.
  • Steven Cohen first reported a position in Corvus Pharmaceuticals in Q1 2017 and held it in 13 quarters.
  • Steven Cohen's Corvus Pharmaceuticals position peaked at $47.6M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.